Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 13/20 | 0.43 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24744747 | 0.93 | CRBN (0.41) | CRBNDDB1BRD9TNFALDH1A1 | |
| SCHEMBL24773134 | 0.86 | CRBN (0.44) | CRBNDDB1BRD9ALDH1A1CHRM2 | |
| SCHEMBL24745329 | 0.84 | CRBN (0.56) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL21896543 | 0.80 | CRBN (0.46) | CRBNDDB1BRD9ALDH1A1CHRM2 | |
| SCHEMBL22907323 | 0.79 | CRBN (0.42) | CRBNDDB1BRD9ALDH1A1CHRM2 | |
| SCHEMBL30275748 | 0.78 | BRD9 (0.42) | CRBNDDB1BRD9 | |
| SCHEMBL26147996 | 0.78 | BRD9 (0.42) | CRBNDDB1BRD9 | |
| SCHEMBL22532036 | 0.77 | CRBN (0.53) | CRBNDDB1TNFALDH1A1CHRM2 | |
| SCHEMBL29549308 | 0.77 | CRBN (0.53) | CRBNDDB1TNFALDH1A1CHRM2 | |
| SCHEMBL20153869 | 0.77 | CRBN (0.60) | CRBNDDB1TNFALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022253713-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |